{"id":"piposulfan","rwe":[{"pmid":"9220288","year":"1997","title":"Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.","finding":"","journal":"Investigational new drugs","studyType":"Clinical Study"},{"pmid":"8932448","year":"1996","title":"Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs.","finding":"","journal":"Pharmaceutical research","studyType":"Clinical Study"},{"pmid":"191037","year":"1976","title":"[Novel Bis-sulfonic Acid Esters with Cytostatic Activity (author's transl)].","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"},{"pmid":"5556760","year":"1971","title":"Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma.","finding":"","journal":"Life sciences. Pt. 2: Biochemistry, general and molecular biology","studyType":"Clinical Study"},{"pmid":"4910386","year":"1970","title":"[Treatment of chronic myeloid leukemia and lymphoreticular sarcoma with piposulfan].","finding":"","journal":"Deutsche medizinische Wochenschrift (1946)","studyType":"Clinical Study"}],"tags":[{"label":"piposulfan","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"ancyte","offLabel":[],"synonyms":["piposulfan","ancyte"],"timeline":[],"approvals":[],"brandName":"Ancyte","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"piposulfan","explanation":"Think of Ancyte like a key that fits into a lock, but instead of unlocking a door, it blocks a specific process in the body. This process is controlled by an enzyme or a series of chemical reactions, and Ancyte's presence helps to slow it down or prevent it from happening. By doing so, Ancyte may help to treat certain conditions, but more research is needed to understand its effects.","oneSentence":"Ancyte works by inhibiting a specific enzyme or pathway, although the exact details of its mechanism are not well understood.","technicalDetail":"Ancyte's mechanism of action is not well characterized, but it is believed to involve the inhibition of a specific enzyme or pathway, potentially through competitive binding or allosteric modulation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3475","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PIPOSULFAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:25:16.045831","biosimilars":[],"competitors":[],"genericName":"piposulfan","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"VY5DPN1TDU","CHEBI":"CHEBI:135606","INN_ID":"1959","UMLSCUI":"C0663942","ChEMBL_ID":"CHEMBL472696","KEGG_DRUG":"D05487","PUBCHEM_CID":"17458","MESH_SUPPLEMENTAL_RECORD_UI":"C107303"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":9,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1997","pmid":"9220288","title":"Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.","journal":"Investigational new drugs"},{"date":"1996 Feb","pmid":"8932448","title":"Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs.","journal":"Pharmaceutical research"},{"date":"1976","pmid":"191037","title":"[Novel Bis-sulfonic Acid Esters with Cytostatic Activity (author's transl)].","journal":"Arzneimittel-Forschung"},{"date":"1971 Jun 8","pmid":"5556760","title":"Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma.","journal":"Life sciences. Pt. 2: Biochemistry, general and molecular biology"},{"date":"1970 May 22","pmid":"4910386","title":"[Treatment of chronic myeloid leukemia and lymphoreticular sarcoma with piposulfan].","journal":"Deutsche medizinische Wochenschrift (1946)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ancyte, also known as piposulfan, is a small molecule drug of the piposulfan class. Its target and exact mechanism of action are unknown. It is not clear if Ancyte is FDA-approved or commercially available. Further information on its approved indications, half-life, bioavailability, generic manufacturers, and patent status is not available. As a result, its commercial status and key safety considerations cannot be determined.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}